FYB.DE

Formycon AG [FYB.DE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

FYB.DE Stock Summary

Top 10 Correlated ETFs

FYB.DE

Top 10 Correlated Stocks

FYB.DE

In the News

FYB.DE Financial details

Company Rating
-
Market Cap
820.16M
Income
34.49M
Revenue
102.94M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
224
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
20.27
Forward P/E
-
PEG
-0.53
P/S
20.08
P/B
1.59
P/C
-
P/FCF
-18.7
Quick Ratio
0.32
Current Ratio
0.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
3.41
EPS next Y
-
EPS next Q
-
EPS this Y
-318.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
28.42%
Revenue last 5Y
-0.23%
Revenue Q/Q
76.19%
EPS Q/Q
-103.78%
-
-
-
-
SMA20
17.73%
SMA50
20.21%
SMA100
-50.59%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
14%
ROC
0.03%
Gross Margin
99%
Oper. Margin
29%
Profit Margin
85%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
44.4-81.1
52W High
-67.16%
52W Low
-39.55%
RSI
54.71
Rel Volume
1.64
Avg Volume
7.56K
Volume
12.37K
Perf Week
-2.03%
Perf Month
14.9%
Perf Quarter
-51.37%
Perf Half Y
-49.33%
-
-
-
-
Beta
0.809
-
-
Volatility
0.45%, 2.26%
Prev Close
2.5%
Price
26.6
Change
0.57%

Something similar

Top by Market Cap
AMZ.DE
TSLA
JPM
FB2A.DE
BRK-B
Top Correlated ETFs
VGEK.DE
VGEJ.DE
W311.DE
HTMW.DE
HTWO.MI
Top Correlated Stocks
0W4N.L
GAYAPROJ.NS
1142.HK
BDT.DE
IUR.DE
Similar Market Cap
ACIC
BANKA.NS
RSKD
WILJX
TERASOFT.NS

Company Profile

Healthcare Biotechnology
  • Volume Average 7.56K
  • Market Capitalization 820.16M
  • Employee 224
  • CEO Dr. Stefan Glombitza
  • Headquarters Planegg,DE
  • IPO Date 2011-01-04
  • Website https://www.formycon.com

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.